Table 1 Summary of studies on VRC maintenance doses to achieve the target range in Asian populations
From: Clinical application of voriconazole in pediatric patients: a systematic review
Study population | No. of samples | Target Ctrough (mg/L) | Maintenance dose to achieve the target range | Year | Country | Reference | |
|---|---|---|---|---|---|---|---|
Age group (years) | Administration routes and VRC Dose (median [range], mg/kg twice daily) | ||||||
Pediatric cancer patients with IA | 27 | 1.0–6.0 | < 12 ≥ 12 | PO 6.3 a IV 5.6 a PO 4.1 a IV 4.1 a | 2013 | Korea | Choi et al. [8] |
Pediatric patients with tumor | 20 | 1.0–5.0 | ≤ 5 6–12 ≥ 13 | PO 15.05 a IV 6.55 a PO 4.75 a IV 4.75 a PO 4.35 a IV 2.75 a | 2016 | Japan | Kato et al. [9] |
Children with immunodeficiencies | 107 | 1.0-5.5 | 0–12 | IV 5- < 7 | 2017 | China | Liu et al. [10] |
Children with hematological diseases | 42 | 1.0-5.5 | < 6 6–12 > 12 | PO 11.1 (6.7–13.8) PO 7.2 (4.2–10.3) IV 5.8 (5.0-7.7) PO 5.3 (4.0-8.5) IV 4.9 (3.6–6.3) | 2018 | China | Hu et al. [11] |
Children with hematological diseases | 108 | 0.5-5.0 | CYP2C19 NMs and ≤ 12 CYP2C19 NMs and > 12 CYP2C19 IMs/PMs and ≤ 12 CYP2C19 IMs/PMs and > 12 | 6.53 ± 2.08 b 3.95 ± 0.85 b 5.75 ± 1.73 b 4.23 ± 0.76 b | 2021 | China | Tian et al. [12] |
Immunocompromised children | 91 | 1.0–5.0 | CYP2C19 NMs CYP2C19 IMs CYP2C19 PMs | 10.4 (8.1–13.4) 9.1 (6.65–10.9) 7.6 (5.35–9.55) | 2022 | China | Chen et al. [13] |
Children with hematological diseases | 131 | 1.0-5.5 | 2–14 | PO 4.75 ± 2.05 b IV 5.21 ± 1.81 b | 2023 | China | Hu et al. [14] |